- Home
- RCUS vs USPH Comparison
RCUS vs USPH Comparison
Compare RCUS & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- USPH
- Stock Information
- Founded
- RCUS 2015
- USPH 1990
- Country
- RCUS United States
- USPH United States
- Employees
- RCUS N/A
- USPH N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- USPH Medical/Nursing Services
- Sector
- RCUS Health Care
- USPH Health Care
- Exchange
- RCUS Nasdaq
- USPH Nasdaq
- Market Cap
- RCUS 1.2B
- USPH 1.3B
- IPO Year
- RCUS 2018
- USPH 1992
- Fundamental
- Price
- RCUS $12.20
- USPH $85.68
- Analyst Decision
- RCUS Buy
- USPH Strong Buy
- Analyst Count
- RCUS 8
- USPH 4
- Target Price
- RCUS $20.71
- USPH $110.25
- AVG Volume (30 Days)
- RCUS 772.4K
- USPH 165.9K
- Earning Date
- RCUS 11-05-2025
- USPH 11-04-2025
- Dividend Yield
- RCUS N/A
- USPH 2.10%
- EPS Growth
- RCUS N/A
- USPH 116.39
- EPS
- RCUS N/A
- USPH 2.29
- Revenue
- RCUS $262,000,000.00
- USPH $722,201,000.00
- Revenue This Year
- RCUS N/A
- USPH $18.74
- Revenue Next Year
- RCUS N/A
- USPH $6.07
- P/E Ratio
- RCUS N/A
- USPH $37.53
- Revenue Growth
- RCUS 6.07
- USPH 16.25
- 52 Week Low
- RCUS $6.50
- USPH $62.77
- 52 Week High
- RCUS $18.98
- USPH $101.20
- Technical
- Relative Strength Index (RSI)
- RCUS 75.43
- USPH 59.00
- Support Level
- RCUS $10.40
- USPH $82.24
- Resistance Level
- RCUS $11.84
- USPH $84.58
- Average True Range (ATR)
- RCUS 0.54
- USPH 2.26
- MACD
- RCUS 0.16
- USPH -0.27
- Stochastic Oscillator
- RCUS 98.35
- USPH 55.93
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.